Drug
ARX788 clinical trials
Also written ARX788.
Keep track of what changes. Save the ARX788 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2021 | 4 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 6
Ambrx, Inc. (3) · Fudan University (3) · Caigang Liu (1) · Henan Cancer Hospital (1) · QuantumLeap Healthcare Collaborative (1) · Zhejiang Medicine Co., Ltd. (1)
Often tested with
Tested in the same studies.
Shr-1258 dimaleate (1) · Trebananib (1) · Trastuzumab (1) · Ado-Trastuzumab Emtansine (1) · Pertuzumab (1) · STA 9090 (1) · Pexidartinib (1) · Talazoparib (1)
Studies
Open first, then newest update. How each study uses ARX788 is read from its arms, and is right about nine times in ten.
Testing it · 10
- ARX788 in HER2-positive Metastatic Breast Cancer PatientsRecruitingPhase 2Henan Cancer HospitalNCT06663748Written as ARX788
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as ARX788
- ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXdNot yet recruitingPhase 2Fudan UniversityNCT06578286Written as ARX788
- ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)Active, not recruitingPhase 2Ambrx, Inc.NCT04829604Written as ARX788
- A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer PatientsActive, not recruitingPhase 2/3Caigang LiuNCT05426486Written as ARX788
- A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)CompletedPhase 1Ambrx, Inc.NCT03255070Written as ARX788
- ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)WithdrawnPhase 2Ambrx, Inc.NCT05041972Written as ARX788
- ARX788 in HER2-positive Breast Cancer Patients With Brain MetastasesStatus unknownPhase 2Fudan UniversityNCT05018702Written as ARX788
- ARX788 in Breast Cancer With Low Expression of HER2Status unknownPhase 2Fudan UniversityNCT05018676Written as ARX788
- A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 ExpressionTerminatedPhase 1Zhejiang Medicine Co., Ltd.NCT02512237Written as ARX788
Given in every arm · 1 — ARX788 is usual care beside what is tested
Codes
What other systems call ARX788 · ClinicalTrials.gg INT001432
- MeSH (NLM) C000710874ARX788One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000710874 | ARX788 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.